Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond. Backed by Lightspeed.
About the role
As the Senior Director of Trade and Channel Management reporting to the Vice President of Market Access, you will be responsible for the strategic design, implementation, and optimization of a high-performing distribution network that ensures patient access while maximizing commercial value.
What they're looking for
- Education : Bachelor’s degree required, MBA or advanced degree in supply chain management or healthcare administration preferred
- Experience : 15+ years of progressive leadership experience in pharmaceutical trade and distribution, with a proven track record of working with partners in specialty pharmacy, distribution and 3PL
- Therapeutic Knowledge : Experience with oral oncology products is required and knowledge of the oncology provider space, specifically large and complex customers (GPOs, Institutions, IDNs, etc…) will be essential
- Technical Expertise : Knowledge and experience with key Trade and Distribution technologies, well as with relevant federal and state legislation
- Strategic Negotiation : Demonstrated success in leading high-stakes negotiations with national wholesalers and large-scale oncology providers
- Launch Leadership : Extensive experience leading trade strategy for successful U.S. product launches, particularly in the oncology drug space, with relevant and recent experience launching oral oncology products
More about this role
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to...
Browse similar: Startup jobs